In these osteolytic tumors, osteoclastogenesis is activated by PTH-related protein (PTHrP) secretion by the tumor cell or by receptor activator of nuclear factor kappa-B ligand (RANKL) secreted by the tumor cell and/or BM-MSCs [147,148]. Here, TNFSF11 is linked to neoplasm.